BECN1 and breast carcinoma: As with other biomarkers in breast cancer, it will be important to examine the expression of Beclin-1 in different histologic and molecular subtypes as was done in a study by Cha et al. [90], who showed that ILC had lower expression of Beclin-1 compared to IDC; in ILC, Beclin-1 expression correlated significantly with ER negativity and was variably expressed according to molecular subtypes, with the highest expression in triple-negative breast cancer.